Fred Aslan returns to biotech as president of Vividion; Zai Lab scoops Portola's Tao Fu to spearhead US operations
→ After a stint as CEO of a medical device company, Receptos co-founder and Venrock alum Fred Aslan is back in the drug development business. As president and chief business officer of Vividion Therapeutics, he will play a crucial role in engineering deals to finance the multiple applications of Vividion’s synthetic and proteomic chemistry platforms, which has already scored a big collaboration with Celgene. Vividion has also wooed Larry Burgess — longtime exec at Array Biopharma — to become its head of chemistry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.